About Prellis Biologics
Prellis Biologics is a Healthcare company based in San Francisco (United States) founded in 2016. Provider of 3D bioprinting technology to build human tissues for drug development. It operates in the Healthcare and Technology sectors. Prellis Biologics has raised $69.85 million across 7 funding rounds from investors including Khosla Ventures, Celesta and Avidity Partners. The company has 22 employees. Prellis Biologics offers products and services including EXIS™ Platform and LNO™. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is PRELLIS BIOLOGICS, INC. Its competitors include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Prellis Biologics was founded in 2016 in San Francisco, United States, within the biotechnology sector. Human tissues are constructed using 3D bioprinting technology for drug development purposes, while human organs for transplantation are also being developed. A laser-based printing process is employed to form layers of extracellular matrix with embedded cells, eliminating needs for cell-seeding or curing. Organoids have been created, and prototype microvasculature is under construction.
- Headquarters San Francisco, United States
- Employees 22
- SectorsHealthcareTechnology
- Phone•••• ••••
- Website prellisbio.com
- Social LinkedIn X Facebook
- Legal Name Prellis Biologics, Inc
- Total Equity Funding$69.85M (USD)
in 7 rounds
- Latest Funding Round$35M (USD), Series C
Jul 2022
- InvestorsKhosla Ventures
& 9 more
- Employee Count22
Products & Services of Prellis Biologics
Prellis Biologics offers a comprehensive portfolio of products and services, including EXIS™ Platform and LNO™.
AI-integrated system for rapid antibody screening and therapeutic development.
3D bioprinted organoids replicating human immune responses for research.
Funding Insights of Prellis Biologics
Prellis Biologics has successfully raised a total of $69.85M across 7 strategic funding rounds. The most recent funding activity was a Series C round of $35 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $69.85M
- Total Rounds 7
- Last Round Series C — $35M
- First Round $250,000
(May 2017)
- Investors Count 10
All 7 funding rounds of Prellis Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | $35M | Series C | – | Celesta Capital, Avidity Partners | |
| Jul 2021 | $19.25M | Series B | – | Celesta Capital | |
| May 2020 | $4.3M | Series A | – | Future Ventures, Khosla Ventures | – |
| Mar 2019 | $8.74M | Series A | – | Khosla Ventures | |
| Jan 2018 | $460,000 | Series A | – | – | – |
| Jul 2017 | $1.85M | Seed | – | True Ventures | |
| May 2017 | $250,000 | Seed | – | IndieBio | – |
10 investors in total: 10 institutional.
Investors in Prellis Biologics
Prellis Biologics has secured backing from 10 investors, including venture fund investors. Prominent investors backing the company include Khosla Ventures, Celesta and Avidity Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on multiple sectors | celesta.vc | San Francisco, United States | ||
Venture capital firm focused on multiple sectors | Dallas, United States | |||
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Venture capital and accelerator services are provided across multiple sectors. | sosv.com | Cork, Ireland | ||
Venture capital firm supporting AI founders through investments and community. | trueventures.com | |||
Early-stage startups are funded by Lucas Venture Group. | lucasvg.com | Palo Alto, United States | ||
Biotech startups are accelerated through IndieBio's focused programs. | indiebio.co | San Francisco, United States | ||
Venture capital is provided to health tech and biology innovations. | civilizationventures.com | San Francisco, United States | ||
| 415ventures.com | ||||
Future Ventures is focused on early-stage venture capital investments. | future.ventures | Los Altos, United States |
Investor details for Prellis Biologics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Prellis Biologics
22 people are tracked at Prellis Biologics (5 in leadership, 17 in team); the tracked headcount is 22.
| Name | Role | Group |
|---|---|---|
Robin Green | Scientific Director Of Platforms | Leadership |
Bhushan Mahadik | Director, Tissue Engineering | Leadership |
Randall Lowe | Senior Director, Chemistry | Leadership |
Mike Nohaile | CEO | Leadership |
Larry Grace | Chief Business Officer; Other Roles | Leadership |
Meha Patel | Principal Associate Scientist | Team |
Keelin Davis | Research Associate | Team |
Andrew Carolan | Operations Manager | Team |
Matt Niemiec | Controller | Team |
Jen Grinder | Research Associate I | Team |
Natalie Marks | Senior Biomedical Engineer | Team |
Madison McKinney | Associate Scientist | Team |
Shivakshi Gupta | Principal Associate Scientist | Team |
Maryam Ridha | Senior Scientist | Team |
Giovanna Rappocciolo | Senior Scientist IV | Team |
Les Miranda | CSO | Team |
Michael Levinson | Scientist II | Team |
Lindsey Facen | Senior Associate Scientist | Team |
Andrei Rusa | Principal Associate Scientist | Team |
Dan Huang | Research Associate II | Team |
2 more people are available in the full profile.
Complete people profiles for Prellis Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Prellis Biologics
3 dated milestones of Prellis Biologics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Prellis Biologics is founded.
- Funding First funding round of $250K.
- Funding Latest funding round, Series C, of $35.0M.
Competitors of Prellis Biologics
Prellis Biologics has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed competitors of Prellis Biologics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Prellis Biologics
The website of Prellis Biologics (prellisbio.com) receives about 4.9K visits a month.
- Monthly visits4.9K
▲ 32.2% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Prellis Biologics (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prellis Biologics
Complete news archive for Prellis Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prellis Biologics
Prellis Biologics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Prellis Biologics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Prellis Biologics is a funded company, having raised a total of $69.85M across 7 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on May 2017.
Prellis Biologics has 22 employees.
Prellis Biologics was founded in 2016 in San Francisco, United States, within the biotechnology sector. Human tissues are constructed using 3D bioprinting technology for drug development purposes, while human organs for transplantation are also being developed. A laser-based printing process is employed to form layers of extracellular matrix with embedded cells, eliminating needs for cell-seeding or curing. Organoids have been created, and prototype microvasculature is under construction.
Prellis Biologics's top competitors include Sutro Biopharma, Avidity Biosciences and Vividion Therapeutics.
Prellis Biologics offers EXIS™ Platform and LNO™.
Prellis Biologics has 10 investors. Key investors include Khosla Ventures, Celesta, Avidity Partners, SOSV, and True Ventures.
Prellis Biologics operates through Prellis Biologics, Inc.